This is a clinical update, not a financial earnings report. The FDA alignment and Phase 2 data are positive for the ATH434 program, but the stock's reaction will depend on upcoming End-of-Phase 2 meeting results and any partnership announcements. Monitor for mid-2026 FDA meeting outcomes and potential collaboration deals.
Price Chart
Executive Summary
Alterity Therapeutics reported Q3 FY26 progress, highlighting FDA alignment on key Phase 3 program elements for ATH434 in MSA and new Phase 2 efficacy data. Cash position of A$44.53M provides runway, but no revenue or EPS figures were reported, making this a clinical/regulatory update rather than a financial earnings release.
Key Facts
- Cash balance of A$44.53 million as of March 31, 2026
- Operating cash outflows of A$4.73 million for the quarter
- FDA Type C meetings supported clinical pharmacology, non-clinical development, and CMC elements for Phase 3
- End-of-Phase 2 FDA meeting on track for mid-year 2026
- New Phase 2 data showed ATH434 slowed disease progression vs placebo on MuSyCA composite endpoint (p=0.034 for 50 mg dose)
- Appointed Dr. Daniel Claassen as Chief Medical Advisor and Ms. Ann Cunningham to Board
- Engaging with pharmaceutical companies for potential strategic collaboration on ATH434
Financial Impact
No revenue or EPS reported; cash position A$44.53M with quarterly burn A$4.73M, implying ~9 quarters runway
Risk Factors
- Clinical trial failure or regulatory setback in Phase 3
- Dependence on ATH434 as sole pipeline asset
- Need for additional financing beyond current cash runway
- No revenue generating operations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3284716 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 6-K | $2.09 | awaiting T+60 | — | $2.20 (−5.26%) |
Oct 23, 2026 4d ago | 6-K | $2.09 | awaiting T+60 | — | $2.20 (+5.26%) |
Oct 23, 2026 4d ago | 6-K | $2.09 | awaiting T+60 | — | $2.20 (+5.26%) |
Oct 21, 2026 6d ago | 6-K | $2.39 | awaiting T+60 | — | $2.20 (−7.95%) |
Oct 21, 2026 6d ago | 6-K | $2.39 | awaiting T+60 | — | $2.20 (−7.95%) |
Oct 19, 2026 8d ago | 6-K | $2.43 | awaiting T+60 | — | $2.20 (−9.47%) |
Oct 9, 2026 18d ago | 6-K | $3.12 | awaiting T+60 | — | $2.20 (−29.49%) |
Oct 5, 2026 22d ago | Press Release | $3.22 | awaiting T+60 | — | $2.20 (−31.68%) |
Oct 5, 2026 22d ago | 6-K | $3.22 | awaiting T+60 | — | $2.20 (−31.68%) |
Sep 25, 2026 4w ago | 6-K | $3.67 | awaiting T+60 | — | $2.20 (−40.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers